The aim of this protocol is to evaluate the tolerability of the Taris placebo system for the development program and to provide key safety and tolerability data for the Taris platform.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
10
Unnamed facility
Phoenix, Arizona, United States
Safety, tolerability and retention of the TARIS placebo system upon insertion, 14-day exposure and removal
Time frame: 14 days
Subject reported symptoms
Time frame: 14 days
Routine and microscopic urinalysis
Time frame: 14 days
Urine culture
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.